MedTrace Logo

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy

NCT04184297 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27190

Last updated 2021-11-15

Study results available
· View outcomes & findings →

Summary

To assess the comparative effectiveness of combination Tiotropium and Olodaterol (Tio+Olo) (FDC) compared to combination LAMA/LABA and ICS (fixed or open), and to explore whether this varies across COPD sub populations defined by exacerbation risk

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Tiotropium and Olodaterol (Tio+Olo)

drug

DRUG

Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)

drug

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2019-11-04
Completion
2019-11-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04184297 on ClinicalTrials.gov